282,285 with ITP as one of all the admission diagnoses. Overall, 27% admissions with ITP as primary (children 4%) and 15% admissions with ITP as one of all the diagnoses documented at least one platelet transfusion. On multivariable adjustment the following factors were associated with worsening disease severity and a higher odds of platelet transfusion, adult age (adjOR = 9.03, 95% CI = 7.40-11.02), male gender (adjOR = 1.21, 95% CI = 1.11-1.31), bleeding occurrence (intracranial/gastrointestinal/genitourinary/ epistaxis) (adjOR = 1.78, 95% CI = 1.61-1.96), admission to rural non-teaching hospital (adjOR = 1.85, 95% CI = 1.52-2.22), and small bed-size hospital (adjOR = 1.23, 95% CI = 1.05-1.45). Of admissions reporting platelet transfusions, only 26% reported a bleeding complication, and 11% had a major operating-room surgery/ procedure. Overall, 65% of transfused patients had neither bleeding nor a major operative procedure during the hospitalization.
Admissions with platelet transfusions had a significantly longer mean length of hospitalization 2.2 days (95% CI = 1.96-2.41, p < 0.001), and accrued higher mean total hospital charges; $31,150 USD (95% CI = 27,644-34,656, p < 0.001). However, platelet transfusions were not associated with in-hospital mortality (adjOR = 1.02, 95% CI = 0.73-1.45, p = 0.892).
CONCLUSION:
Platelets are administered to a small fraction of the hospitalized ITP patients. In a majority of these cases however, platelet usage does not appear to be concordant with the current guidelines or associated with improvement in clinical outcomes.
I mmune thrombocytopenia (ITP)
is an autoimmune disorder characterized by increased platelet destruction, resulting in low platelet counts. 1 The annual incidence is estimated to be 5 cases per 100,000 population. 2 Patients with ITP have variable bleeding symptoms; the majority have only mild muco-cutaneous bleeding, but in some there may be severe, life-threatening internal organ bleeding. [2] [3] [4] Therapeutic options in ITP patients to increase the platelet count should balance the risks of significant bleeding with thrombocytopenia versus the potential adverse effects of the treatment such as corticosteroids or intravenous gamma globulin (IVIG). 3, 5, 6 The role of platelet transfusions in the management of ITP remains controversial. The clinical benefit of a platelet transfusion is believed to be limited by the shortened survival of transfused platelets. 7, 8 However, published case series report the efficacy of platelet transfusions alone, [7] [8] [9] [10] in massive doses, [11] [12] [13] [14] Data on the nationwide practice of using platelet transfusion in ITP patients are scarce. We have previously reported an association between platelet transfusions and an increase in arterial thrombosis and mortality in platelet consumptive disorders such as Thrombotic Thrombocytopenic Purpura and Heparin Induced Thrombocytopenia. 16 Practice patterns for platelet transfusions in ITP patients and the clinical utility of platelet transfusions in this patient population remain poorly defined. To bridge this knowledge gap, we utilized a nationally representative database, with the objectives of studying the current platelet transfusion practices, the practice patterns in the use platelet transfusions in ITP patients, the adherence of the practice nationwide with the current guidelines for platelet transfusions, and their impact on healthcare resource utilization in ITP patients.
MATERIALS AND METHODS

Data source and study population
We merged the National Inpatient Sample (NIS) database from 2010-2014 for this analysis. The NIS, developed by the Health Care Utilization Project (HCUP) and sponsored by the Agency for Healthcare Research and Quality (AHRQ), is the largest allpayer database representative of hospital admissions in the US. NIS uses a multi-staged clustering design to provide a stratified probability sample of 20% of all hospital admissions among more than 1,000 US community hospitals. All the participating hospitals by the definition of the American Hospital Association, are non-federal, short-term general, and other specialty hospitals. Specialty hospitals that are represented in the survey include obstetrics/gynecology, ear nose and throat, and orthopedics. Children's hospitals are also represented in the survey. Information in NIS is de-identified data in a typical discharge abstract format, without individual patient or hospitallevel identifiers. These data include one primary or principal diagnosis and up to 29 secondary diagnosis codes, one primary and up to 14 secondary procedure codes, any major operating room procedures during hospitalization, admission and discharge status, demographic information, total charges, expected payment source, the length of hospital stay, and hospital characteristics. The principal diagnosis is the primary reason for admission and is coded in the first diagnosis field. Alllisted diagnoses (Dx1-Dx30) include principal plus additional conditions that either co-exist at the time of admission or that develop during the stay and which have an impact on the treatment or the length of stay in the hospital.
ITP was identified using the international classification of diseases-9-clinical modification (ICD-9-CM) code 287.31. Only patients with ITP as the primary admitting diagnosis were included in the analysis. HCUP guidelines in granting the authors access to NIS data set were followed, and all authors signed the data-use agreement.
Variables and outcomes
Demographic details such as age, gender, and race (categorized as white vs. non-white) and hospital-level characteristics including hospital location (urban vs. rural), teaching vs nonteaching, and bed size (categorized into small, medium, and large according to the criteria defined by HCUP using the region of the US, the urban-rural designation of the hospital), and the teaching status 17 were identified from the database.
All patients refined diagnostic related groups (APRDRG) severity index is a clinical severity index defined by HCUP-NIS that was available for all patients. APRDRGs are a validated inpatient classification system widely used in the US as a case-mix measure and account for the severity of illness, the risk of mortality, prognosis, treatment difficulty, need for intervention and resource intensity. 16 We identified bleeding during the hospitalization and in-hospital mortality for all patients. Bleeding was defined as the occurrence of intracranial hemorrhage (ICH), gastrointestinal (GI) bleed, genitourinary (GU) bleed, or epistaxis. The treatments administered, the total length of hospitalization and the mean cost were also recorded. We used a combination of ICD-9-CM diagnosis and procedure codes to identify these variables (Appendix 1). Data on laboratory values and pharmacological therapies administered during an inpatient stay were not available.
Statistical analysis
All analyses were weighted to produce national-level estimates. Univariate followed by stepwise multivariable regression analysis was performed to assess the factors predicting administration of platelet transfusion. All multivariable models were checked for multi-collinearity. We also determined the in-hospital mortality rates in patients with or without bleeding and in the different treatment subgroups.
We performed a sensitivity analysis using a propensity score-matched analysis to check the robustness of our findings. Using propensity score matching, 1:1 matched controls were created for the patients who received platelet transfusion. For propensity matching, matched controls could only be derived from non-weighted admissions. We defined a priori age, gender, and APRDRG severity index for propensity matching. We then performed logistic regression using the matched pairs to predict platelet transfusions in ITP subjects. Results are expressed as OR and 95% confidence interval. A 2-sided p-value of < 0.05 was considered statistically significant. Statistical analyses were performed using Stata/ IC 15.0 (Stata-Corp., College Station, Texas) and SAS version 9.4.2 (SAS Institute Inc, Cary, North Carolina).
RESULTS
From 2010 to 2014 inclusive, 78,376 patients were admitted to US hospitals with ITP as the primary admission diagnosis.
The mean AE SD age was 45 AE 27 years. Females constituted 56.1% of the total admissions. Children (age < 18 years) constituted 22.1% of the total admissions. Sixty-five percent of the admissions were to urban teaching hospitals, and 64% were to large bed size hospitals. Overall, 17.6% of patients experienced at least one bleeding episode, as defined above, during the hospitalization. At least one platelet transfusion was administered in 27.4% of the admissions. Among the 282,285 hospitalizations where ITP was one of Table 1) . Of the transfused patients, 26.0% experienced at least one bleeding episode (ICH/GI/GU bleeding/Epistaxis) and 10.5% underwent at least one major operating room procedure during the hospitalization. Of note, 65.4% of the patients who received one or more platelet transfusions did not experience a bleeding episode nor underwent a major operating room procedure during the hospital course (Fig. 1) .
Factors associated with the likelihood of receiving a platelet transfusion in adults and children admitted with ITP as the primary diagnosis are described in Table 2 and  Table S1 (Supplementary Table 1 ), respectively. In contrast to adults, in children, the percentage of transfusions were much smaller (4.1% of all hospitalizations).
For sensitivity analysis, using propensity score matching we generated a 1:1 match set for hospitalizations with platelet transfusion with controls matched for age, gender, and APRDRG severity index. Matched controls could only be derived from non-weighted numbers (n = 15,818 unweighted admissions corresponding to n = 78,376 estimated weighted admissions by~20% sampling). After propensity matching we had 4,153 cases and 4,153 controls (Fig. 2) . Matched patients who received platelet transfusion had higher odds of a bleeding episode during hospitalization (OR = 1.80, 95% CI = 1.58-2.05, p < 0.001). Similar to the primary results, among the matched groups the following factors were associated with lower odds of receiving platelet transfusions: patients admitted in the large hospitals (OR = 0.75, 95% CI = 0.65-0.87, p < 0.001), urban academic centers (OR = 0.80, 95% CI = 0.67-0.95, p < 0.01), and patients who underwent splenectomy during the hospital course (OR = 0.61, 95% CI = 0.53-0.70, p < 0.001).
In patients who received platelet transfusions and either underwent splenectomy or other major surgical procedures, the existence of a temporal correlation between the day of platelet transfusion and the day of a major operative procedure suggests that, in at least a subset of patients, transfusion was administered to prevent intra-or post-operative bleeding. Of the patients who underwent splenectomy, and received platelet transfusion (n = 1865) (see Table 1 ), 57.0% of the transfusions were administered on the day of splenectomy. Similarly, of the patients who underwent a major operating room procedure other than splenectomy and received platelet transfusions (n = 396), 30.6% of the cases transfusions were administered on the day of the procedure.
Patients who received platelet transfusion had 2.2 days (95% CI = 1.96-2.41, p < 0.001) longer mean length of hospital stay and accrued $31,150 (95% CI = 27,644-34,656, p < 0.001) higher mean total hospitalization charges, as compared to the patients who did not receive a platelet transfusion.
In-hospital mortality
In multivariable analysis for factors associated with all-cause in-hospital mortality, the following were associated with significantly higher mortality; age ≥ 18 years (adjOR = 3.47, 95% CI = 1.05-12.12, p < 0.05), higher APRDRG severity index (major loss of function-adjOR = 18.08, 95% CI = 9.82-33.60, p < 0.001, and extreme loss of function-adjOR = 204.41, 95% CI = 111.28-364.80, p < 0.001). Platelet transfusions were not associated with in-hospital mortality (adjOR = 1.02, 95% CI = 0.73-1.45, p = 0.892). These results replicate and validate our previous published findings. 16 There was no statistically significant difference in in-hospital mortality among the propensitymatched patients who received platelet transfusion compared to the controls. Overall, all-cause in-hospital mortality was 1.1%. Although the overall percentage of ITP patients receiving platelet transfusion increased from 25.1% in 2010 to 27.0% in 2014, the difference by year was not statistically significant.
DISCUSSION
In the absence of randomized controlled trials, the current understanding of the utility of platelet transfusions in ITP patients is mostly informed by published case series and natural history studies. 2, 18, 19 The role of platelet transfusion in management of ITP remains questionable, due to poorly documented therapeutic effects and shortened survival of transfused platelets in vivo. 7, 8, 20 Case series have reported short term increases in platelet counts following platelet transfusions with amelioration of massive hemorrhage and the prevention of bleeding during invasive surgery, thus providing a rationale for their use in patients with hemorrhage or who are at high risk for bleeding. 13,14 Published Abbreviations: ICH = intracranial hemorrhage, GI = gastrointestinal, GU = genitourinary, APRDRG = all patients refined diagnostic related groups. * Excluded from multivariable analysis as p > 0.1 in univariate analysis. † Bleeding episode was defined as occurrence of either ICH/GI bleed/GU bleed/Epistaxis. ‡ Excluded from multivariable analysis due to multi-collinearity.
guidelines recommend that the use of platelet transfusions in management of ITP be limited to patients with lifethreatening hemorrhage or those in whom an invasive surgical procedure is planned. 3, 4, [21] [22] [23] [24] [25] [26] We observed that two-thirds of the admissions associated with an ITP diagnosis and reporting platelets transfusions in this nationally representative sample had neither a documented bleeding nor a major operating room procedure. There appears to be substantial utilization of platelet transfusions in the management of hospitalized patients with ITP, with transfusions occurring in 15% of admissions with ITP as one of all diagnoses and 27% of admissions with ITP as the primary diagnosis. The high rate of utilization in hospitalized patients with an ITP diagnosis may in part reflect a greater risk of bleeding or the presence of co-morbidities. That over 65% of patients who received a platelet transfusion had neither a documented hemorrhage nor an invasive surgical procedure suggests a practice pattern of utilization of platelet transfusions in patients who are not bleeding or are at high risk for bleeding. It must be noted that since NIS captures hospitalization episodes rather than unique individuals it is probable that the same patient may have undergone multiple hospitalizations with platelet transfusions. Our observation of the use of platelet transfusions in patients without bleeding or high risk for bleeding is corroborated by the observation by Cirasino et al., who report that only 20% of administered platelet transfusions were appropriate and in accordance with current guidelines. 27 We observed platelet transfusions in less than 5% of all admissions in children with ITP. This may reflect the benign course of ITP in pediatric patients, with spontaneous remission in nearly four-fifths of the children 28 and the risk of medical complications including ICH, GI bleed, and mortality being associated with older age at presentation. 18, 21, [29] [30] [31] [32] The findings of higher platelet transfusion rates in rural non-teaching hospitals as compared to urban teaching hospitals, and small centers as compared to large centers suggests a higher concordance of practice with the guidelines in academic centers. This identifies a potential target area for education and improvement in clinical practice. We have previously reported that platelet transfusions were not associated with increased mortality in ITP subjects. 16 This remained true in the current study for subgroup analyses in patients with and without bleeding. Administration of platelet transfusions during the hospital course was associated with significantly longer lengths of hospitalization and higher total hospital charges, even after adjustment for patient demographics, hospital characteristics, and APRDRG severity index. It is possible that the severity and/or duration of thrombocytopenia and response to treatment may affect the length of hospital stay and total hospital cost but these factors cannot be examined in this administrative database. Platelet transfusions are associated with risks include febrile nonhemolytic reactions, allergic reactions, transfusion-related acute lung injury, and bacterial sepsis. [33] [34] [35] We have also demonstrated the lack of survival benefit associated with platelet transfusion. Taken together, these data support the judicious use of platelets only in patients with bleeding or high risk of bleeding as recommended by the current guidelines. This study is subject to several limitations. The NIS databases do not contain any descriptions of the severity of bleeding, the clinical presentation, laboratory tests such as platelet count, and the transfusion threshold levels, all of which might be important determinants of platelet transfusion. Further, this inpatient database does not provide any information on the outpatient treatment of patients, which remains a significant part of ITP management. ITP severe enough to require platelet transfusions will generally be managed as an in-patient and thus this may reflect a sicker patient population warranting more intense interventions like platelet transfusions. Also, as we observe in our results, analyzing the hospitalizations with primary diagnosis and reason for admission being ITP, likely also creates a bias toward higher percentage of platelet transfusions than an analysis of hospitalizations with one in all diagnoses being ITP (27% versus 15%). The same patient could also have been coded more than one time in this analysis, capturing different independent hospitalization events as we cannot link different hospitalizations across same patient in NIS. In the absence of individual identifiers, patients cannot be tracked longitudinally to repeated hospitalizations in same or subsequent years. NIS has previously been extensively validated against the National Hospital Discharge Survey (NHDS) and Medicare Provider Analysis and Review File (MEDPAR). 36 In conclusion, this study demonstrates that the majority of ITP hospitalizations reporting platelet transfusions were restricted to adults and did not meet the criteria for administering platelets based on current guidelines. Platelet transfusions were not related to improved mortality outcomes and given the added risks and costs of what could possibly be unnecessary platelet transfusions, there is a need for adequately powered prospective studies to ascertain the efficacy, risks, and role of platelet transfusion in the management of ITP for adults and children.
